Monthly Archives: March 2016
Most of the pharmaceutical companies continues to face crescent competition in the operating markets from different sources. Some of the solutions to overcome the current difficulties and barriers, may be a constant search of new R&D methods and new operations mechanisms in order to obtain economic scale and gain new commercial capabilities that can drive or improve effectiveness from R&D investments.
The healthcare landscape continues to evolve in complexity for Life Sciences companies. The clear shift of prescribing power from physician prescription influence to integrated and centralized decision-making units is a key example.